Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2022 Earnings Conference Call August 23, 2022 4:30 PM ET

Company Participants

Dan Passeri - Chief Executive Officer

Anish Suri - President & Chief Scientific Officer

Ken Pienta - Acting Chief Medical Officer

Matteo Levisetti - SVP, Clinical Development

Kerri Millar - Chief Financial Officer

Conference Call Participants

Stephen Willey - Stifel

Reni Benjamin - JMP Securities

Mark Breidenbach - Oppenheimer

Operator

Greetings and welcome to the Cue Biopharma Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn this conference over to Mr. Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you, sir. You may begin.

Dan Passeri

Thank you, and good afternoon everyone. Just to remind you, as we proceed through the presentation we'll convey which slide we're on and you can advance the slides directly. We appreciate your time and interest in our update call regarding our ongoing trials of CUE-101, as well as CUE-102. Our initial representative drug candidates of the IL-2-based CUE-100 series.

Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Ken Pienta, our Acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development; and Kerri Millar, our Chief Financial Officer. This conference is being recorded and will be available on our website for the next 30 days. As a reminder, and as shown here on Slide #2 of this presentation. An overview may contain some forward-looking statements, and any forward-looking statements made during the call represents the company’s views only as of today, August 23, 2022.

So Our agenda for today's call is shown on the next slide. As an introduction and each will provide a synopsis of our progress to date, as well as describing our strategic and competitive positioning prior to turning the call over to Ken and Matteo who will each provide a summary and status update of the data associated with observations from our ongoing Phase 1 trials of CUE-101, as well as the recently initiated CUE-102 trial. Following Ken and Matteo, I'll provide an overview of our corporate strategy and additional pipeline expansions within the CUE-100 series. Kerri will then provide a brief update of our financials, after which I'll return for closing remarks and then open up the call for a Q&A session.